|
| Status |
Public on Mar 14, 2021 |
| Title |
Sample_1_AML262_day0 |
| Sample type |
RNA |
| |
|
| Source name |
Primary AML 262
|
| Organism |
Homo sapiens |
| Characteristics |
disease state: Primary AML
tissue: patient-derived xenograft in NSG mice
agent: control
time: Day_0
cell type: AML cells
|
| Treatment protocol |
PDX models were treated with AraC (Cytarabine) for 5 consecutive days with 60 mg/kg (i.p.).
|
| Growth protocol |
Patient-derived AML cells engrafted in NSG mice.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Human AML cells from NSG mice were collected from bones and spleen and purified using an anti-human CD45 antibody after before therapy at day 0 and after therapy at day 8 and day 29.
|
| Label |
biotin
|
| Label protocol |
Total RNAs were reverse transcribed into cDNA, then transcribed and labeled into biotinylated cRNA.
|
| |
|
| Hybridization protocol |
Labeled cRNA products were randomly fragmented and hybridized onto Affymetrix GeneChips.
|
| Scan protocol |
Protocol not available
|
| Description |
AML262_Day_0
|
| Data processing |
CEL files were annotated to refSeq using custom CDF annotation via BrainArray V23. Expression was normalized using rma() function from affy R package.
|
| |
|
| Submission date |
Mar 06, 2020 |
| Last update date |
Mar 14, 2021 |
| Contact name |
Matt Teater |
| E-mail(s) |
mrt2001@med.cornell.edu
|
| Organization name |
Weill Cornell Medical College
|
| Street address |
445 E 69th St
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10021 |
| Country |
USA |
| |
|
| Platform ID |
GPL28228 |
| Series (2) |
| GSE146542 |
Acute myeloid leukemia cells resist chemotherapy through a transient senescence-like state [Array] |
| GSE146544 |
Acute myeloid leukemia cells resist chemotherapy through a transient senescence-like state |
|
